Changeflow GovPing Pharma & Drug Safety Heterotrophic Skin Bacteria Composition for Tre...
Routine Notice Added Final

Heterotrophic Skin Bacteria Composition for Treating UV Damage and PLE

Favicon for changeflow.com USPTO Patent Applications - Therapeutics (A61P)
Published
Detected
Email

Summary

The USPTO published patent application US20260097086A1 by inventor Catherine O'Neill for a composition comprising heterotrophic skin bacteria or bacterial extract for modulating cytokine expression in skin cells. The composition is intended for preventing and treating skin damage caused by UV light and for treating polymorphous light eruption (PLE).

What changed

The USPTO published patent application US20260097086A1 disclosing a composition comprising heterotrophic skin bacteria and/or heterotrophic skin bacterial extract for modulating cytokine expression in skin cells. The composition is claimed for use in preventing and treating skin damage caused by UV light and for treating polymorphous light eruption (PLE). The application was filed on September 20, 2023, and published on April 9, 2026.

This published application provides notice of the claimed invention to the public and establishes a priority date. Pharmaceutical and biotechnology companies developing microbiome-based skincare products, UV protection formulations, or dermatological treatments should review the claims for potential freedom-to-operate concerns. Competitors should monitor this application through grant to assess competitive implications.

What to do next

  1. Monitor for patent grant and issued claims
  2. Conduct freedom-to-operate analysis if developing similar compositions
  3. Assess potential licensing opportunities

Archived snapshot

Apr 9, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

COMPOSITIONS AND USES THEREOF

Application US20260097086A1 Kind: A1 Apr 09, 2026

Inventors

Catherine O'NEILL

Abstract

The present invention relates to a composition comprising a heterotrophic skin bacterium and/or heterotrophic skin bacterial extract for use in the modulation of cytokine expression in a skin cell. The composition is particularly suited for use in the prevention and/or treatment of skin damage caused by UV light and use in treating skin conditions such as polymorphous light eruption (PLE).

CPC Classifications

A61K 35/74 A61K 8/99 A61P 17/00 A61Q 19/004

Filing Date

2023-09-20

Application No.

19113160

View original document →

Named provisions

Compositions and Uses Thereof Modulation of Cytokine Expression Treatment of UV Damage and PLE

Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
USPTO
Published
April 9th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260097086A1

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Patients
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application filing Biotechnology research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Public Health Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.